Clinical significance of Stratifin, ERα and PR promoter methylation in tumor and serum DNA in Indian breast cancer patients

Clinical Biochemistry

Volumn 43, Issue 4-5, 2010, Pages 380-386

  Mirza, Sameer ^a   Sharma, Gayatri ^a   Parshad, Rajinder ^a   Srivastava, Anurag ^a   Gupta, Siddartha Datta ^a   Ralhan, Ranju ^a,b,c  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Breast cancer; DNA methylation; ER ; Gene silencing; PR; Stratifin

Indexed keywords

DNA; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR; STRATIFIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DNA METHYLATION; FEMALE; FOLLOW UP; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDIAN; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE LEVEL;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DNA METHYLATION; DNA, NEOPLASM; ESTROGEN RECEPTOR ALPHA; EXONUCLEASES; FEMALE; GENES, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; INDIA; MIDDLE AGED; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 76749085652     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.11.016     Document Type: Article

References (39)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA. Cancer J. Clin. 55 (2005) 74-108
2. Chopra R. The Indian scene. J. Clin. Oncol. 19 (2001) 106S-111S
3. Saxena S., Rekhi B., Bansal A., Bagga A., Chintamani, and Murthy N.S. Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India-a cross-sectional study. World J. Surg. Oncol. 3 (2005) 67
4. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358 (2008) 1148-1159
5. Fraga M.F., Herranz M., Espada J., Ballestar E., Paz M.F., Ropero S., et al. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res. 64 (2004) 5527-5534
6. Laird P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3 (2003) 253-266
7. Szyf M., Pakneshan P., and Rabbani S.A. DNA methylation and breast cancer. Biochem. Pharmacol. 68 (2004) 1187-1197
8. Evron E., Dooley W.C., Umbricht C.B., Rosenthal D., Sacchi N., Gabrielson E., et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 357 (2001) 1335-1336
9. Fiegl H., Millinger S., Mueller-Holzner E., Marth C., Ensinger C., Berger A., et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. 65 (2005) 1141-1145
10. Anderson E. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res. 4 (2002) 197-201
11. Leu Y.W., Yan P.S., Fan M., Jin V.X., Liu J.C., Curran E.M., et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res. 64 (2004) 8184-8192
12. Giacinti L., Claudio P.P., Lopez M., and Giordano A. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 11 (2006) 1-8
13. Shinozaki M., Hoon D.S., Giuliano A.E., Hansen N.M., Wang H.J., Turner R., et al. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin. Cancer Res. 11 (2005) 2156-2162
14. Lapidus R.G., Ferguson A.T., Ottaviano Y.L., Parl F.F., Smith H.S., Weitzman S.A., et al. Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin. Cancer Res. 2 (1996) 805-810
15. Chan T.A., Hwang P.M., Hermeking H., Kinzler K.W., and Vogelstein B. Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev. 14 (2000) 1584-1588
16. Gasco M., Bell A.K., Heath V., Sullivan A., Smith P., Hiller L., et al. Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res. 62 (2002) 2072-2076
17. Henrique R., Jeronimo C., Hoque M.O., Carvalho A.L., Oliveira J., Teixeira M.R., et al. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions. DNA Cell Biol. 24 (2005) 264-269
18. Iwata N., Yamamoto H., Sasaki S., Itoh F., Suzuki H., Kikuchi T., et al. Frequent methylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 19 (2000) 5298-5302
19. Kunze E., Wendt M., and Schlott T. Promoter methylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas. Int. J. Mol. Med. 18 (2006) 547-557
20. Suzuki H., Itoh F., Toyota M., Kikuchi T., Kakiuchi H., and Imai K. Inactivation of the 14-3-3 sigma gene is associated with 5′ CpG island methylation in human cancers. Cancer Res. 60 (2000) 4353-4357
21. Umbricht C.B., Evron E., Gabrielson E., Ferguson A., Marks J., and Sukumar S. Methylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 20 (2001) 3348-3353
22. Lewis C.M., Cler L.R., Bu D.W., Zochbauer-Muller S., Milchgrub S., Naftalis E.Z., et al. Promoter methylation in benign breast epithelium in relation to predicted breast cancer risk. Clin. Cancer Res. 11 (2005) 166-172
23. Frommer M., McDonald L.E., Millar D.S., Collis C.M., Watt F., Grigg G.W., et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 1827-1831
24. Ferguson A.T., Evron E., Umbricht C.B., Pandita T.K., Chan T.A., Hermeking H., et al. High frequency of methylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 6049-6054
25. Sasaki M., Dharia A., Oh B.R., Tanaka Y., Fujimoto S., and Dahiya R. Progesterone receptor B gene inactivation and CpG methylation in human uterine endometrial cancer. Cancer Res. 61 (2001) 97-102
26. Mirza S., Sharma G., Prasad C.P., Parshad R., Srivastava A., Gupta S.D., et al. Promoter methylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci. 81 (2007) 280-287
27. Simooka H., Oyama T., Sano T., Horiguchi J., and Nakajima T. Immunohistochemical analysis of 14-3-3 sigma and related proteins in hyperplastic and neoplastic breast lesions, with particular reference to early carcinogenesis. Pathol. Int. 54 (2004) 595-602
28. Pertschuk L.P., Kim D.S., Nayer K., Feldman J.G., Eisenberg K.B., Carter A.C., et al. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer 66 (1990) 1663-1670
29. Rhodes A., Jasani B., Anderson E., Dodson A.R., and Balaton A.J. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am. J. Clin. Pathol. 118 (2002) 408-417
30. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 629-656
31. Sharma G., Mirza S., Prasad C.P., Srivastava A., Gupta S.D., and Ralhan R. Promoter methylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci. 80 (2007) 1873-1881
32. Adams B.D., Furneaux H., and White B.A. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol. Endocrinol. 21 (2007) 1132-1147
33. Osada H., Tatematsu Y., Yatabe Y., Nakagawa T., Konishi H., Harano T., et al. Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers. Oncogene 21 (2002) 2418-2424
34. Martinez-Galan J., Torres B., Del Moral R., Munoz-Gamez J.A., Martin-Oliva D., Villalobos M., et al. Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biol. Ther. 7 (2008) 958-965
35. Laronga C., Yang H.Y., Neal C., and Lee M.H. Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J. Biol. Chem. 275 (2000) 23106-23112
36. Yang H.Y., Wen Y.Y., Chen C.H., Lozano G., and Lee M.H. 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol. Cell. Biol. 23 (2003) 7096-7107
37. Akahira J., Sugihashi Y., Suzuki T., Ito K., Niikura H., Moriya T., et al. Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin. Cancer Res. 10 (2004) 2687-2693
38. Feng W., Shen L., Wen S., Rosen D.G., Jelinek J., Hu X., et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res. 9 (2007) R57
39. Sobin L.H., and Fleming I.D. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80 (1997) 1803-1804